{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T17:34:03.911353+00:00","company":{"ticker":"PFE","cik":78003,"company_name":"PFIZER INC"},"pagination":{"limit":100,"returned":21,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"ma_counterparty":[{"display_name":"Seagen Inc.","detail":"acquisition","count":2,"first_seen":"2023-12-14T23:59:59+00:00","last_seen":"2023-12-14T23:59:59+00:00","evidence_fact_ids":[88497,88498]}]},"facts":[{"fact_type":"earnings_release","fact_key":"e111b24f39e531b393580ff1cbd99657cfb566e7","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"0.47","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"2,687","period_text":"the first quarter of 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"$14,451"},"claim":"PFIZER INC reported the first quarter of 2026 results: revenue $14,451, net income 2,687, EPS 0.47. Guidance reaffirmed.","evidence_excerpt":"rates (5) . Results for the first quarter of 2026 and 2025 (6) are summarized below. ($ in millions, except per share amounts) First-Quarter 2026 2025 % Change Revenues $ 14,451 $ 13,715 5% Reported (3) Net Income 2,687 2,967 (9%) Reported (3) Diluted EPS 0.47 0.52 (10%) Adjusted (4) Income 4,290 5,237 (18%) Adjusted (4) Diluted EPS 0.75 0.92 (18%)","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-26-000053","anchor_url":"https://secwatch.observer/filing/0000078003-26-000053#claim-e111b24f39e531b393580ff1cbd99657cfb566e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/0000078003-26-000053-index.htm"},{"fact_type":"executive_change","fact_key":"d8b87f2c6c","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-10-15T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-10","interim":false,"role":"member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mortimer J. Buckley was elected as member of the Board at PFIZER INC.","evidence_excerpt":"elected Mortimer J. Buckley to serve as a member of the Company’s Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-24-000185","anchor_url":"https://secwatch.observer/filing/0000078003-24-000185#claim-d8b87f2c6c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000185/0000078003-24-000185-index.htm"},{"fact_type":"executive_change","fact_key":"b4ac2552aa","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-07-10T23:59:59+00:00","payload":{"action":null,"action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Chief Scientific Officer and President, Pfizer Research & Development","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Mikael Dolsten departed as Chief Scientific Officer and President, Pfizer Research & Development at PFIZER INC.","evidence_excerpt":"On July 9, 2024, Pfizer Inc. (the \"Company\") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-24-000130","anchor_url":"https://secwatch.observer/filing/0000078003-24-000130#claim-b4ac2552aa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000130/0000078003-24-000130-index.htm"},{"fact_type":"executive_change","fact_key":"d1e02b0ddd","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-27","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Cyrus Taraporevala was elected as Director at PFIZER INC.","evidence_excerpt":"elected Cyrus Taraporevala to serve as a member of the Company’s Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-24-000127","anchor_url":"https://secwatch.observer/filing/0000078003-24-000127#claim-d1e02b0ddd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000127/0000078003-24-000127-index.htm"},{"fact_type":"earnings_release","fact_key":"49b9335ca2f4b1e455976c85fe3c529bb980f3ca","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-05-01T23:59:59+00:00","payload":{"eps_text":"$0.55","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$3,115 million","period_text":"first quarter of 2024","report_date":"2024-05-01","result_type":"reported_results","revenue_text":"$14,879 million"},"claim":"PFIZER INC reported first quarter of 2024 results: revenue $14,879 million, net income $3,115 million, EPS $0.55. Guidance raised.","evidence_excerpt":"First-Quarter 2024 Results ▪ Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities ▪ First-Quarter 2024 Revenues of $14.9 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove a Year-Over-Year Operational Decrease in Revenues of 19% – Excluding Contributions from Comirnaty (1) and","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-24-000103","anchor_url":"https://secwatch.observer/filing/0000078003-24-000103#claim-49b9335ca2f4b1e455976c85fe3c529bb980f3ca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/0000078003-24-000103-index.htm"},{"fact_type":"shareholder_vote","fact_key":"828bc06c89d23e3744e4407aebd2f13b3907f1f6","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"failed","proposal_text":"Publish a Report on Corporate Contributions","proposal_type":"other","results":[{"broker_non_votes":"893,428,132","subject":null,"votes_abstain":"59,125,487","votes_against":"3,505,075,475","votes_for":"137,986,751","votes_withheld":null}]},"claim":"PFIZER INC shareholders rejected Publish a Report on Corporate Contributions at the 2024-04-25 meeting.","evidence_excerpt":"8. The shareholder proposal to Publish a Report on Corporate Contributions was not approved based upon the following votes: Votes for approval 137,986,751 Votes against 3,505,075,475 Abstentions 59,125,487 Broker non-votes 893,428,132","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000078003-24-000101","anchor_url":"https://secwatch.observer/filing/0000078003-24-000101#claim-828bc06c89d23e3744e4407aebd2f13b3907f1f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101-index.htm"},{"fact_type":"shareholder_vote","fact_key":"96d1961dfcafa736096d7160db8de77f0d88cbe2","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"failed","proposal_text":"Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures","proposal_type":"other","results":[{"broker_non_votes":"893,428,132","subject":null,"votes_abstain":"63,015,226","votes_against":"3,123,669,364","votes_for":"515,502,691","votes_withheld":null}]},"claim":"PFIZER INC shareholders rejected Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures at the 2024-04-25 meeting.","evidence_excerpt":"6. The shareholder proposal to Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures was not approved based upon the following votes: Votes for approval 515,502,691 Votes against 3,123,669,364 Abstentions 63,015,226 Broker non-votes 893,428,132","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000078003-24-000101","anchor_url":"https://secwatch.observer/filing/0000078003-24-000101#claim-96d1961dfcafa736096d7160db8de77f0d88cbe2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b2c83b59f408290cd652df9b4374d5319bdea3ad","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"failed","proposal_text":"Adopt an Independent Board Chair Policy","proposal_type":"other","results":[{"broker_non_votes":"893,428,132","subject":null,"votes_abstain":"26,511,479","votes_against":"2,391,266,871","votes_for":"1,284,408,190","votes_withheld":null}]},"claim":"PFIZER INC shareholders rejected Adopt an Independent Board Chair Policy at the 2024-04-25 meeting.","evidence_excerpt":"5. The shareholder proposal to Adopt an Independent Board Chair Policy was not approved based upon the following votes: Votes for approval 1,284,408,190 Votes against 2,391,266,871 Abstentions 26,511,479 Broker non-votes 893,428,132","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000078003-24-000101","anchor_url":"https://secwatch.observer/filing/0000078003-24-000101#claim-b2c83b59f408290cd652df9b4374d5319bdea3ad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101-index.htm"},{"fact_type":"shareholder_vote","fact_key":"23408f85e4ea944913cfbff6bf3ae8b67246880e","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"passed","proposal_text":"Advisory approval of executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"893,428,132","subject":null,"votes_abstain":"26,256,736","votes_against":"315,293,726","votes_for":"3,360,637,251","votes_withheld":null}]},"claim":"PFIZER INC shareholders approved Advisory approval of executive compensation at the 2024-04-25 meeting.","evidence_excerpt":"4. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes: Votes for approval 3,360,637,251 Votes against 315,293,726 Abstentions 26,256,736 Broker non-votes 893,428,132","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000078003-24-000101","anchor_url":"https://secwatch.observer/filing/0000078003-24-000101#claim-23408f85e4ea944913cfbff6bf3ae8b67246880e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101-index.htm"},{"fact_type":"shareholder_vote","fact_key":"50a2849345ce260a31aadf32ca796ffa995b0725","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"passed","proposal_text":"Approval of Amended and Restated Pfizer Inc. 2019 Stock Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"893,428,132","subject":null,"votes_abstain":"20,560,066","votes_against":"275,998,451","votes_for":"3,405,629,196","votes_withheld":null}]},"claim":"PFIZER INC shareholders approved Approval of Amended and Restated Pfizer Inc. 2019 Stock Plan at the 2024-04-25 meeting.","evidence_excerpt":"3. The proposal to approve the Amended and Restated Pfizer Inc. 2019 Stock Plan was approved based upon the following votes : Votes for approval 3,405,629,196 Votes against 275,998,451 Abstentions 20,560,066 Broker non-votes 893,428,132","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000078003-24-000101","anchor_url":"https://secwatch.observer/filing/0000078003-24-000101#claim-50a2849345ce260a31aadf32ca796ffa995b0725","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d902ebe2dd5ac74f5ea3aa706017059f2170a0e5","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"passed","proposal_text":"Ratification of KPMG LLP as independent registered public accounting firm for 2024","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"23,201,615","votes_against":"256,738,678","votes_for":"4,315,675,552","votes_withheld":null}]},"claim":"PFIZER INC shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for 2024 at the 2024-04-25 meeting.","evidence_excerpt":"2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2024 fiscal year was approved based upon the following votes: Votes for approval 4,315,675,552 Votes against 256,738,678 Abstentions 23,201,615 Broker non-votes n/a","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000078003-24-000101","anchor_url":"https://secwatch.observer/filing/0000078003-24-000101#claim-d902ebe2dd5ac74f5ea3aa706017059f2170a0e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f5c44a0b1ab485438c816ccde69acd44f61497e6","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"893,428,132","subject":"Ronald E. Blaylock","votes_abstain":"16,147,043","votes_against":"74,828,190","votes_for":"3,611,209,480","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Albert Bourla","votes_abstain":"13,129,674","votes_against":"272,930,253","votes_for":"3,416,127,786","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Susan Desmond-Hellmann","votes_abstain":"15,485,733","votes_against":"76,819,517","votes_for":"3,609,882,463","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Joseph J. Echevarria","votes_abstain":"16,687,322","votes_against":"151,136,693","votes_for":"3,534,360,661","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Scott Gottlieb","votes_abstain":"13,967,122","votes_against":"46,699,897","votes_for":"3,641,520,694","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Helen H. Hobbs","votes_abstain":"15,401,666","votes_against":"127,638,461","votes_for":"3,559,147,586","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Susan Hockfield","votes_abstain":"15,843,439","votes_against":"46,187,757","votes_for":"3,640,156,517","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Dan R. Littman","votes_abstain":"16,332,328","votes_against":"83,205,522","votes_for":"3,602,649,863","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Shantanu Narayen","votes_abstain":"16,074,375","votes_against":"61,360,816","votes_for":"3,624,752,522","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"Suzanne Nora Johnson","votes_abstain":"17,657,077","votes_against":"174,627,508","votes_for":"3,509,903,128","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"James Quincey","votes_abstain":"16,945,319","votes_against":"76,444,804","votes_for":"3,608,797,590","votes_withheld":null},{"broker_non_votes":"893,428,132","subject":"James C. Smith","votes_abstain":"18,229,764","votes_against":"117,466,325","votes_for":"3,566,491,624","votes_withheld":null}]},"claim":"PFIZER INC shareholders approved Election of Directors at the 2024-04-25 meeting.","evidence_excerpt":"1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 14, 2024 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000078003-24-000101","anchor_url":"https://secwatch.observer/filing/0000078003-24-000101#claim-f5c44a0b1ab485438c816ccde69acd44f61497e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101-index.htm"},{"fact_type":"earnings_release","fact_key":"036607f476c6ab1ed62a81eb46fdf199b30e340d","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-01-30T23:59:59+00:00","payload":{"eps_text":"$2.05 to $2.25","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2024","report_date":"2024-01-30","result_type":"guidance_update","revenue_text":"$58.5 to $61.5 Billion"},"claim":"PFIZER INC reported full-year 2024 results: revenue $58.5 to $61.5 Billion, EPS $2.05 to $2.25. Guidance reaffirmed.","evidence_excerpt":"Annual Net Cost Savings by End of 2024 from Previously Announced Cost Realignment Program ▪ Reaffirms Full-Year 2024 Guidance (5) Provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted (3) Diluted EPS of $2.05 to $2.25 NEW YORK, Tuesday, January 30, 2024 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-24-000017","anchor_url":"https://secwatch.observer/filing/0000078003-24-000017#claim-036607f476c6ab1ed62a81eb46fdf199b30e340d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm"},{"fact_type":"earnings_release","fact_key":"1e03e19483a491aca922e5cb68ee7f512362305a","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-01-30T23:59:59+00:00","payload":{"eps_text":"($0.60)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($3,369) million","period_text":"fourth-quarter 2023","report_date":"2024-01-30","result_type":"reported_results","revenue_text":"$14.2 Billion"},"claim":"PFIZER INC reported fourth-quarter 2023 results: revenue $14.2 Billion, net income ($3,369) million, EPS ($0.60).","evidence_excerpt":"$0.37, Down 93% Year-Over-Year, and Adjusted (3) Diluted EPS of $1.84, Down 72% Year-Over-Year, Significantly Impacted by One-Time Events (4) ▪ Fourth-Quarter 2023 Revenues of $14.2 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 42% Operational Decrease in Fourth-Quarter Revenues – Excluding Contributions from Comirnaty (1) and Paxlovid,","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-24-000017","anchor_url":"https://secwatch.observer/filing/0000078003-24-000017#claim-1e03e19483a491aca922e5cb68ee7f512362305a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm"},{"fact_type":"earnings_release","fact_key":"4647c4c0bcbc0ebc70c53d07a37e22a1b0eb2568","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2024-01-30T23:59:59+00:00","payload":{"eps_text":"$0.37","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$2,119 million","period_text":"full-year 2023","report_date":"2024-01-30","result_type":"reported_results","revenue_text":"$58.5 Billion"},"claim":"PFIZER INC reported full-year 2023 results: revenue $58.5 Billion, net income $2,119 million, EPS $0.37.","evidence_excerpt":"Launched Significant Number of New Products and Indications; and Realigned Commercial Organization to Improve Focus, Speed and Execution ▪ Full-Year 2023 Revenues of $58.5 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 41% Operational Decrease in Year-Over-Year Revenues – Excluding Contributions from Comirnaty (1) and Paxlovid,","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-24-000017","anchor_url":"https://secwatch.observer/filing/0000078003-24-000017#claim-4647c4c0bcbc0ebc70c53d07a37e22a1b0eb2568","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm"},{"fact_type":"ma_transaction","fact_key":"1c7160259368917f75f0c9bd3a9e5a73d63e3b2d","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2023-12-14T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-12-14","consideration_text":"$229 in cash per share, for a total enterprise value of approximately $43 billion","counterparty":"Seagen Inc.","effective_date":"2023-12-14","item_codes_triggered":["2.01"]},"claim":"PFIZER INC completed an acquisition involving Seagen Inc. for $229 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).","evidence_excerpt":"Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-295562","anchor_url":"https://secwatch.observer/filing/0001193125-23-295562#claim-1c7160259368917f75f0c9bd3a9e5a73d63e3b2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000119312523295562/0001193125-23-295562-index.htm"},{"fact_type":"ma_transaction","fact_key":"7705a59bc3796f6b2c01737251b0cc6b154e6fab","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2023-12-14T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-12-14","consideration_text":"$229.00 in cash per share, for a total enterprise value of approximately $43 billion","counterparty":"Seagen Inc.","effective_date":"2023-12-14","item_codes_triggered":["2.01"]},"claim":"PFIZER INC completed an acquisition involving Seagen Inc. for $229.00 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).","evidence_excerpt":"Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-294930","anchor_url":"https://secwatch.observer/filing/0001193125-23-294930#claim-7705a59bc3796f6b2c01737251b0cc6b154e6fab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/0001193125-23-294930-index.htm"},{"fact_type":"executive_change","fact_key":"de10cfbfa6","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2023-12-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"retirement","effective_date":"2023-12-15","interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Angela Hwang resigned as Chief Commercial Officer at PFIZER INC.","evidence_excerpt":"As a result of this reorganization, the role currently held by Angela Hwang, Chief Commercial Officer, Executive Vice President, is being eliminated and she will cease serving in her current role and as a member of the Company’s Executive Leadership Team effective as of December 15, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-23-000118","anchor_url":"https://secwatch.observer/filing/0000078003-23-000118#claim-de10cfbfa6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm"},{"fact_type":"executive_change","fact_key":"5d3056b3b3","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2023-12-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-12-15","interim":false,"role":"Chief International Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Alexandre de Germay was appointed as Chief International Commercial Officer at PFIZER INC.","evidence_excerpt":"the Pfizer International Commercial Division, which will be led by Alexandre de Germay, who will join Pfizer as Chief International Commercial Officer, Executive Vice President, and will report to Dr. Bourla.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-23-000118","anchor_url":"https://secwatch.observer/filing/0000078003-23-000118#claim-5d3056b3b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm"},{"fact_type":"executive_change","fact_key":"a5242225b5","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2023-12-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-12-15","interim":false,"role":"Chief U.S. Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Aamir Malik was appointed as Chief U.S. Commercial Officer at PFIZER INC.","evidence_excerpt":"the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S. Commercial Officer, Executive Vice President, and continue reporting to Dr. Bourla","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-23-000118","anchor_url":"https://secwatch.observer/filing/0000078003-23-000118#claim-a5242225b5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm"},{"fact_type":"executive_change","fact_key":"eb56f50607","cik":78003,"ticker":"PFE","company_name":"PFIZER INC","filed_at":"2023-12-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-12-15","interim":false,"role":"Chief Oncology Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Chris Boshoff was appointed as Chief Oncology Officer at PFIZER INC.","evidence_excerpt":"Pfizer will create an end-to-end business organization called Pfizer Oncology Division, which will integrate certain Oncology Commercial and R&D operations from both Pfizer and Seagen and will be led by Dr. Chris Boshoff, who will become Chief Oncology Officer, Executive Vice President, and continue reporting to Dr. Albert Bourla, Chairman and Chief Executive Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000078003-23-000118","anchor_url":"https://secwatch.observer/filing/0000078003-23-000118#claim-eb56f50607","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm"}]}